HMP Global January 3, 2025

Jo Varshney, DVM, PhD, founder and CEO of VeriSIM Life

In this interview, Dr Jo Varshney, founder and CEO of VeriSIM Life, discusses the complexities of drug development, the role of AI in accelerating discovery, the integration of real-world evidence, and strategies to reduce costs while advancing innovation.

Please state your name, title, and any relevant professional experience.

Jo Varshney, DVM, PhD: Hello, I’m Dr Jo Varshney. I am the founder and CEO of VeriSIM Life and our pharmaceutical subsidiary, PulmoSIM Therapeutics. I am a veterinarian with a PhD in comparative oncology/genomics, and I serve on several advisory boards, including the Critical Path Institute.

What are the key stages of drug development, and how do they influence the likelihood...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Biotechnology, Interview / Q&A, Pharma, Pharma / Biotech, Technology, Trends
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
23andMe is potentially selling more than just genetic data. Survey info is just as much a privacy problem
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?

Share This Article